Cargando…

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

BACKGROUND: Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making proc...

Descripción completa

Detalles Bibliográficos
Autores principales: Frigerio, Isabella, Malleo, Giuseppe, de Pastena, Matteo, Deiro, Giacomo, Surci, Niccolò, Scopelliti, Filippo, Esposito, Alessandro, Regi, Paolo, Giardino, Alessandro, Allegrini, Valentina, Bassi, Claudio, Girelli, Roberto, Salvia, Roberto, Butturini, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383677/
https://www.ncbi.nlm.nih.gov/pubmed/35976466
http://dx.doi.org/10.1245/s10434-022-12385-4
_version_ 1784769408905773056
author Frigerio, Isabella
Malleo, Giuseppe
de Pastena, Matteo
Deiro, Giacomo
Surci, Niccolò
Scopelliti, Filippo
Esposito, Alessandro
Regi, Paolo
Giardino, Alessandro
Allegrini, Valentina
Bassi, Claudio
Girelli, Roberto
Salvia, Roberto
Butturini, Giovanni
author_facet Frigerio, Isabella
Malleo, Giuseppe
de Pastena, Matteo
Deiro, Giacomo
Surci, Niccolò
Scopelliti, Filippo
Esposito, Alessandro
Regi, Paolo
Giardino, Alessandro
Allegrini, Valentina
Bassi, Claudio
Girelli, Roberto
Salvia, Roberto
Butturini, Giovanni
author_sort Frigerio, Isabella
collection PubMed
description BACKGROUND: Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process. METHODS: This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods. RESULTS: Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS. CONCLUSIONS: We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
format Online
Article
Text
id pubmed-9383677
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-93836772022-08-17 Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver Frigerio, Isabella Malleo, Giuseppe de Pastena, Matteo Deiro, Giacomo Surci, Niccolò Scopelliti, Filippo Esposito, Alessandro Regi, Paolo Giardino, Alessandro Allegrini, Valentina Bassi, Claudio Girelli, Roberto Salvia, Roberto Butturini, Giovanni Ann Surg Oncol Pancreatic Tumors BACKGROUND: Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process. METHODS: This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods. RESULTS: Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS. CONCLUSIONS: We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection. Springer International Publishing 2022-08-17 2022 /pmc/articles/PMC9383677/ /pubmed/35976466 http://dx.doi.org/10.1245/s10434-022-12385-4 Text en © Society of Surgical Oncology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Pancreatic Tumors
Frigerio, Isabella
Malleo, Giuseppe
de Pastena, Matteo
Deiro, Giacomo
Surci, Niccolò
Scopelliti, Filippo
Esposito, Alessandro
Regi, Paolo
Giardino, Alessandro
Allegrini, Valentina
Bassi, Claudio
Girelli, Roberto
Salvia, Roberto
Butturini, Giovanni
Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
title Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
title_full Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
title_fullStr Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
title_full_unstemmed Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
title_short Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
title_sort prognostic factors after pancreatectomy for pancreatic cancer initially metastatic to the liver
topic Pancreatic Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383677/
https://www.ncbi.nlm.nih.gov/pubmed/35976466
http://dx.doi.org/10.1245/s10434-022-12385-4
work_keys_str_mv AT frigerioisabella prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT malleogiuseppe prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT depastenamatteo prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT deirogiacomo prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT surciniccolo prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT scopellitifilippo prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT espositoalessandro prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT regipaolo prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT giardinoalessandro prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT allegrinivalentina prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT bassiclaudio prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT girelliroberto prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT salviaroberto prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver
AT butturinigiovanni prognosticfactorsafterpancreatectomyforpancreaticcancerinitiallymetastatictotheliver